CervoMed's Phase 2b study extension shows improved cognitive outcomes with neflamapimod, leading to an analyst upgrade and ...
CervoMed has announced positive results from the extension phase 2b RewinD-LB study of neflamapimod for dementia with Lewy ...
A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p<0.001 vs. old capsules; ...
JonesResearch upgraded CervoMed (CRVO) to Buy from Hold with a $15 price target arguing that the company’s latest data from the open label ...
CervoMed (Nasdaq: CRVO) has announced encouraging findings from the first 16 weeks of the extension phase of its Phase IIb ...
CervoMed's neflamapimod capsules show increased efficacy in treating dementia with Lewy bodies, with promising safety results and lower fall incidence. The new capsules led to higher plasma ...
Hosted on MSN1mon
CervoMed reports progress in dementia drug trialBOSTON - CervoMed Inc. (NASDAQ:CRVO), a clinical-stage company developing treatments for neurologic disorders, announced preliminary findings from its Phase 2b RewinD-LB trial for neflamapimod ...
Hosted on MSN22d
Why CervoMed (CRVO) Is Advancing TodayNeflamapimod is a potential treatment for dementia with Lewy bodies. A scientist in the lab, researching the development of biopharmaceutical monoclonal antibody drugs.
These data will play an important role in our evaluation of the next steps in the development of neflamapimod.” The data set from the double-blind phase of the RewinD-LB trial presented today at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback